Ryan is a 2nd year PhD candidate in the Tate Group, jointly funded by the EPSRC Institute for Chemical Biology CDT and an AstraZeneca CASE studentship. His research is focussed on the design and application of novel tools and technologies for de novo target identification in heath and disease. Specifically, Ryan's project is focussed on a novel small molecule anticancer therapy that failed to progress to clinical trials due to toxicity concerns. Using the tools of affinity-based protein profiling and chemical proteomics, Ryan hopes to understand more about the interactions this molecule has with both cancer cells and the healthy cells of the body.
Z. Wang et al., Cancer Res., 2018, 78, 6691-6702. http://cancerres.aacrjournals.org/content/78/23/6691.long